The Biosimilars Bill Checks Out — "Cuts Red Tape" Is a Fair Description of What FDA's Own Research Supports

Healthcare Source: Facebook Post MOSTLY TRUE

Original source →

Why this matters

Not every claim needs to reveal a gap. This one is included for completeness and because it involves a real regulatory tradeoff (safety-study requirements vs. faster/cheaper drug access) worth documenting accurately either way.

Statement

Source: Facebook, July 15, 2026

“I’m proud to introduce the bipartisan Expedited Access to Biosimilars Act. It cuts unnecessary U.S. Food and Drug Administration red tape, speeds access to more affordable treatments, and increases competition. Our bill keeps rigorous safety standards in place while helping patients and families save on prescription drugs.”

The Facts

1. The bill is real, bipartisan, and he is the sponsor. The House bill is H.R. 9661, the Expedited Access to Biosimilars Act, introduced July 14, 2026 and referred to Energy & Commerce. The primary govinfo BILLSTATUS roster lists Rep. Nicholas A. Langworthy [R-NY-23] as the sponsor, co-led with Rep. Kim Schrier (D-WA) — so “I’m proud to introduce” is accurate (verified against the primary roster, not news coverage). A companion Senate bill, S. 1414, exists in the 119th Congress.

2. What it actually changes: current law generally requires biosimilar manufacturers to run clinical studies assessing immunogenicity, pharmacodynamics, and comparative clinical efficacy against the reference biologic before FDA approval. The bill would make those specific studies discretionary — FDA could still require them, with written justification, but would no longer have to require them by default.

3. “Cuts unnecessary red tape” is a defensible, not empty, characterization. FDA’s own published research and a peer-reviewed meta-analysis literature base have found no significant safety or efficacy differences in patients switched between biosimilars and reference products, which is the scientific basis proponents cite for calling comparative-switching studies frequently redundant. “Unnecessary” is FDA’s and the sponsors’ characterization of the studies being made discretionary, not this site’s independent finding — but it is supported by that research record, not merely asserted.

4. “Keeps rigorous safety standards in place” also holds up. The bill does not eliminate FDA’s authority to require additional studies — it shifts the default and requires HHS to give written notice and scientific justification when it does require them. FDA retains full discretion.

Context

Roswell Park Comprehensive Cancer Center (Buffalo) publicly supports the bill, citing biosimilars’ growing role in cancer treatment. No patient-safety organization or professional medical association opposing this specific bill was found in the public record as of this entry’s publication. Some clinicians and patients have expressed general reservations about switching a stable patient to a biosimilar (a longstanding clinical-practice debate independent of this bill), but that is a different question from whether the comparative-switching studies this bill deregulates are scientifically necessary for approval.

Sources

Note: House sponsorship was verified against the primary govinfo BILLSTATUS roster (H.R. 9661), not an aggregator, per this site’s sponsor-verification standard. The Facebook post itself cannot be archived to Wayback (login wall); see archive_note in the frontmatter.

Last updated: July 17, 2026.